You just read:

FDA Provides Cornerstone Pharmaceuticals Approval to Initiate Pivotal Study for CPI-613, its Metabolism-Directed Anticancer Compound

News provided by

Cornerstone Pharmaceuticals, Inc.

23 Mar, 2017, 10:15 ET